Literature DB >> 17962214

Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis.

B Cherie Millar1, Bernard D Prendergast, John E Moore.   

Abstract

Over the last decade, a novel methicillin-resistant Staphylococcus aureus (MRSA) has emerged, primarily associated with healthy individuals within the community. This organism is distinct from healthcare-associated MRSA (HA-MRSA) in terms of epidemiology, microbiology and clinical manifestation and as such has been defined as community-associated MRSA (CA-MRSA). Given that S. aureus is a major aetiological agent of infective endocarditis (IE), particularly associated with the iv drug user population, reports of IE attributed to CA-MRSA are now emerging in the literature. The aims of this article are to (i) define and contrast CA-MRSA with HA-MRSA; (ii) review the published cases of CA-MRSA IE to date; and (iii) evaluate the current international recommendations for antibiotic prophylaxis and treatment regimens for IE in relation to CA-MRSA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962214     DOI: 10.1093/jac/dkm410

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

Review 1.  Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

Authors:  Leticia I Llarrull; Jed F Fisher; Shahriar Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

2.  Complementary analysis of the vegetative membrane proteome of the human pathogen Staphylococcus aureus.

Authors:  Susanne Wolff; Hannes Hahne; Michael Hecker; Dörte Becher
Journal:  Mol Cell Proteomics       Date:  2008-05-06       Impact factor: 5.911

3.  Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.

Authors:  A Kirby; C Edwards; C M Broughton; N J Williams
Journal:  Infection       Date:  2011-04-01       Impact factor: 3.553

4.  Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.

Authors:  Jose L Raygada; Donald P Levine
Journal:  Am Health Drug Benefits       Date:  2009-02

5.  Clinical and laboratory features of invasive community-onset methicillin-resistant Staphylococcus aureus infection: a prospective case-control study.

Authors:  M C Wehrhahn; J O Robinson; J C Pearson; F G O'Brien; H L Tan; G W Coombs; E M Pascoe; R Lee; P Salvaris; R Salvaris; D New; R J Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-12       Impact factor: 3.267

6.  Risk factors for multidrug-resistant organisms among deceased organ donors.

Authors:  Judith A Anesi; Emily A Blumberg; Jennifer H Han; Dong H Lee; Heather Clauss; Antonette Climaco; Richard Hasz; Esther Molnar; Darcy Alimenti; Sharon West; Warren B Bilker; Pam Tolomeo; Ebbing Lautenbach
Journal:  Am J Transplant       Date:  2019-06-26       Impact factor: 8.086

Review 7.  Acute infective endocarditis.

Authors:  Jay R McDonald
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

8.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.

Authors:  G Luo; B Spellberg; T Gebremariam; H Lee; Y Q Xiong; S W French; A Bayer; A S Ibrahim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-01       Impact factor: 3.267

9.  Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals.

Authors:  Erica M C D'Agata; Glenn F Webb; Mary Ann Horn; Robert C Moellering; Shigui Ruan
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

10.  Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA.

Authors:  Jingru Meng; Hui Wang; Zheng Hou; Tao Chen; Jingguo Fu; Xue Ma; Gonghao He; Xiaoyan Xue; Min Jia; Xiaoxing Luo
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.